HY-004 (Juventas Cell Therapy)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameHY-004 (Juventas Cell Therapy)
Drug Alias Namedual anti-CD19/anti-CD22 CAR T-cell (Juventas Cell Therapy)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulatorsT lymphocytes stimulants +[4] 
TargetsCD22B-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesJuventas Cell Therapy Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJuventas Cell Therapy Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A